Zhongqiu Zhang, MD
Surgery · Middlebury, CTNPI 1679725816
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $75,000 of the $82,728 with a category attached, or 90.7%. Davol Inc. accounts for 99.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $79,028 and has fallen 95.8% since, to $3,297 in 2025. Among surgery clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $3063.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$82K
- Olympus America Inc.$98
- Medtronic$48
- E.r. Squibb & Sons, L.L.C.$35
- Smith+Nephew$34
- Heron Therapeutics, Inc.$34
- plus $229 from 11 others
What the payments were for
- Royalty or licence$75,00091%
- Speaking & faculty fees$7,1789%
- Food & beverage$5501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 7 | $82,250 |
| Olympus America Inc. | 1 | $98 |
| Medtronic | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Smith+Nephew | 2 | $34 |
| Heron Therapeutics, Inc. | 2 | $34 |
| CSL Behring | 1 | $30 |
| Integra Lifesciences Corporation | 1 | $25 |
| Kerecis Limited | 1 | $25 |
| Biogen | 1 | $24 |
| Lemaitre Vascular, Inc. | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Amgen | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Intuitive Surgical | 1 | $14 |
How this compares
$82,728 in reported general payments places this provider in the 95th percentile of 289 surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 39 | $20,607 |
| Lubiprostone | 13 | $2,188 |
| LoperamideLoperamide Hcl | 32 | $653 |
| Ondansetron Hcl | 11 | $192 |
| Neomycin Sulfate | 35 | $184 |
| Metronidazole | 38 | $89 |
| Oxycodone Hcl | 26 | $86 |
| Tamsulosin Hcl | 12 | $63 |
| Pantoprazole Sodium | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other surgery in Middlebury
- Juan HolguinMiddlebury$13K
- John MortonNew Haven$970K
- Joseph AferzonPortland$712K
- Andrew DuffyNew Haven$256K
- Sherard ChiuFairfield$148K
- Nikhilesh SekharFairfield$140K
- Anees ChagparNew Haven$121K
- Roselle CrombieFairfield$113K
- Craig FlochNorwalk$88K
- Mark FariesNew Haven$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.